Lialda (mesalamine) is a prescription brand-name medication. The Food and Drug Administration (FDA) has approved it to treat ulcerative colitis in adults and certain children. To use this drug, ...

Philadelphia, PA – October 17, 2007 – According to a study using a dynamic in vitro gastrointestinal tract system, Shire plc's (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) ulcerative colitis drug LIALDA™ ...

Basingstoke, UK and Philadelphia, PA, US – March 19, 2007 – Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) today announced the availability of LIALDA™ (mesalamine) with MMXTM Technology, indicated for ...

After years of patent battles, the last legal barrier between Shire and a generic version of its lucrative ulcerative colitis drug Lialda has fallen and the FDA has approved a generic from Zydus ...

To induce remission in active, mild-to-moderate ulcerative colitis. Mesalamine is an anti-inflammatory agent that is commonly used as a treatment for the induction of remission in patients with ...

today announced that the U.S. Food and Drug Administration (FDA) approved Lialda® (mesalamine) Delayed Release Tablets for the maintenance of remission in patients with ulcerative colitis. This ...

A US court has upheld Shire's patent on its Lialda (mesalamine) ulcerative colitis delayed release tablets, in a legal tussle with Allergan subsidiaries Watson Pharma and Watson Laboratories. Watson ...

March 28 (Reuters) - A U.S. district court on Monday ruled in favor of Shire Plc, preventing Allergan Plc from selling generic versions of Lialda, the ulcerative colitis drug, in the United States ...

Shire shares have taken a bashing following late-stage data which showed that its ulcerative colitis drug Lialda has failed as a potential treatment for diverticulitis. Shire shares have taken a ...

In fiscal 2015, Lialda added $684.4 million to Shire's (SHPG) top line, reflecting an 8% annual increase in sales. This was supported by a 10% rise in prescription volume. Despite the price increase, ...

LIALDA¢â€ž¢ (mesalamine) with MMX¢â€ž¢ Technology - the First Oral Once-Daily Mesalamine for Active, Mild to Moderate Ulcerative Colitis - Now Available Basingstoke, UKand Philadelphia, PA, US - March ...